Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.
Under the... Read More.


